Literature DB >> 106479

Antibacterial activity of nitroxoline and sulphamethizole alone and in combination in urinary tract infections.

M R Jacobs, R G Robinson, H J Koornhof.   

Abstract

In vitro studies on the antibacterial activity of nitroxoline and sulphamethizole, alone and in combination, were undertaken and minimal inhibitory concentrations (MICs) determined on a range of urinary pathogens. Eighty per cent of the strains tested were sensitive to less than or equal to 16 mg/l of nitroxoline, and all strains, including Pseudomonas aeruginosa and Streptococcus faecalis, were sensitive to less than or equal to 64 mg/l of nitroxoline. No synergism could be demonstrated with sulphamethizole, but the combination was antagonistic when tested against strains of Ps. aeruginosa and Strep. faecalis. An in vivo study on 10 volunteers showed excellent urinary levels of nitroxoline and sulphamethizole after an oral dose of 160 mg of each agent, and 6-hour urinary nitroxoline levels were greater than or equal to 64 mg/l in 9 of the 10 subjects, and sulphamethizole levels were greater than or equal to 64 mg/l in all 10 subjects. Laboratory findings suggest that nitroxoline and sulphamethizole are both suitable agents for use in urinary tract infections caused by organisms sensitive to these agents, but there appears to be litte advantage in using them in combination.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 106479

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

1.  In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany.

Authors:  Michael Kresken; Barbara Körber-Irrgang
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

2.  Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).

Authors:  Hongchao Jiang; Jori E Taggart; Xiaoxi Zhang; Doris M Benbrook; Stuart E Lind; Wei-Qun Ding
Journal:  Cancer Lett       Date:  2011-07-06       Impact factor: 8.679

3.  Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains.

Authors:  C Pelletier; P Prognon; P Bourlioux
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 4.  Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections.

Authors:  Kurt G Naber; Hiltrud Niggemann; Gisela Stein; Guenter Stein
Journal:  BMC Infect Dis       Date:  2014-11-27       Impact factor: 3.090

5.  Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation.

Authors:  Maite Ibáñez de Garayo; Wendi Liu; Nicole C Rondeau; Christopher B Damoci; J J L Miranda
Journal:  J Antibiot (Tokyo)       Date:  2021-06-23       Impact factor: 2.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.